MAP2K1 and neoplasm: Since EVs could contain antigens and MHC (Andre et al., 2002, 2002; Koga et al., 2005; Raposo et al., 1996; Wolfers et al., 2001), we next tested the therapeutic effect of MEK1‐hi EVs on a third party tumour, using B16F10 as a model system.